Close this search box.

Treat Your Patients’ Basal Cell Carcinoma with the Revolutionary SRT-100™

August 16, 2016

Any dermatologist knows just how devastating a skin cancer diagnosis can be to his or her patients. Skin cancer is diagnosed nearly three times as often as any other form of cancer, with the most common of all skin cancers being basal cell carcinoma.

While patients facing basal cell carcinoma have multiple choices available for the treatment of their skin cancer, are you offering your patients the best treatment available? The majority of treatment options for skin cancer involve a surgical procedure of some type, whether it is excisional surgery, electrosurgery, cryosurgery, laser surgery or Mohs micrographic surgery.

Give your patients peace of mind with a painless, safe and highly effective non-surgical option for the treatment of basal cell carcinoma: the SRT-100™.

Sensus Healthcare’s SRT-100™ delivers a precise, calibrated dose of Superficial Radio Therapy that only goes skin deep. This low-dose of Superficial Radio Therapy safely destroys non-melanoma skin cancer without damaging healthy surrounding tissue. There is no need for anesthesia, no cutting or stitching, less risk for infection, and no need for patients to undergo reconstructive plastic surgery to repair surgical scars. With the SRT-100™, patients heal quickly from their basal cell carcinoma treatment with no downtime or lifestyle restrictions following the procedure.

Performed right in your office, Superficial Radio Therapy with the SRT-100™ delivers optimum results to treat non-melanoma skin cancer without the negative side effects of invasive treatments. This treatment is ideal for your patients diagnosed with non-melanoma skin cancer who also have health risks that prevent them from undergoing surgical treatment, or patients who wish to avoid the pain and scarring associated with surgery.

For the physician, SRT-100™ offers many unique features including: broad range of motion; compact, mobile design, precise and accurate x-ray delivery; variable applicator sizes; and replaceable contact shields.

Sensus Healthcare’s SRT-100™ has cure rates comparable to those of surgical skin cancer treatment options and has been cleared by the U.S. Food and Drug Administration for the treatment of non-melanoma skin cancer. It is ideal for private dermatology and oncology practices, as well as hospitals and multi-locale healthcare providers.

Give your patients a non-surgical, painless and effective basal cell carcinoma treatment. Contact Sensus Healthcare today to learn more about the SRT-100™.